Compare GFL Environmental Inc. Subordinate voting shares no par value (GFL) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GFL Environmental Inc. Subordinate voting shares no par value vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? GFL Environmental Inc. Subordinate voting shares no par value trades at $42.2 (market cap $18.33B), while Iovance Biotherapeutics Inc. Common Stock trades at $13.5 (market cap $5.85B). The key difference: GFL Environmental Inc. Subordinate voting shares no par value is far larger — about 3.1× Iovance Biotherapeutics Inc. Common Stock's market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GFL Environmental Inc. Subordinate voting shares no par value for 0 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| GFL | IOVA | |
|---|---|---|
Market Cap | $18.33B | $5.85B |
Volume | 2,954,733 | 14,517,176 |
Sector | Industrials | Health |
52-Week High | $46.51 | $14.82 |
52-Week Low | $33.54 | $1.81 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $25.33B | $5.78B |
Dividend Yield | 0.16% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
